Cadence Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Cadence Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-33,605	Closed	-$1.09M	–	288
2020 Q2	$1.09M	Buy	33,605 +1,437	+4%	+$51.5K	0.16%	201
2020 Q1	$1.31M	Sell	32,168 -2,180	-6%	-$116K	0.22%	135
2019 Q4	$2.12M	Sell	34,348 -5,655	-14%	-$375K	0.23%	117
2019 Q3	$2.92M	Sell	40,003 -281	-0.7%	-$21K	0.41%	64
2019 Q2	$3.31M	Sell	40,284 -20,346	-34%	-$1.45M	0.33%	64
2019 Q1	$4.28M	Buy	60,630 +583	+1%	+$34.3K	0.38%	52
2018 Q4	$2.7M	Buy	60,047 +4,663	+8%	+$244K	0.27%	96
2018 Q3	$3.13M	Buy	55,384 +9,276	+20%	+$568K	0.17%	152
2018 Q2	$3.08M	Buy	46,108 +20,947	+83%	+$1.31M	0.18%	126
2018 Q1	$1.47M	Buy	25,161 +835	+3%	+$53K	0.1%	301
2017 Q4	$1.57M	Sell	24,326 -9,076	-27%	-$565K	0.1%	270
2017 Q3	$1.75M	Buy	33,402 +27,005	+422%	+$1.29M	0.11%	220
2017 Q2	$299K	Buy	6,397 +345	+6%	+$16.6K	0.02%	602
2017 Q1	$300K	Sell	6,052 -2,440	-29%	-$137K	0.02%	608
2016 Q4	$515K	Sell	8,492 -8,337	-50%	-$510K	0.04%	499
2016 Q3	$1.12M	Sell	16,829 -112	-0.7%	-$7K	0.08%	284
2016 Q2	$946K	Buy	16,941 +554	+3%	+$26.9K	0.07%	301
2016 Q1	$552K	Buy	16,387 +9,060	+124%	+$307K	0.04%	455
2015 Q4	$331K	Sell	7,327 -497	-6%	-$21.4K	0.02%	534
2015 Q3	$309K	Sell	7,824 -2,340	-23%	-$133K	0.02%	521
2015 Q2	$631K	Sell	10,164 -6,456	-39%	-$384K	0.04%	498
2015 Q1	$1.04M	Buy	+16,620	New	+$1.01M	0.06%	398

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cadence Capital Management's ANIP Position: Q3 2020 in Review

Cadence Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2020, closing a stake of 33,605 shares — an estimated $1.09M sold.

Cadence Capital Management first reported a position in ANIP in Q1 2015 and held it in 22 quarters. The position peaked at $4.28M in Q1 2019. 116 funds tracked by Wall St. Rank hold ANIP as of Q3 2020.

Cadence Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Cadence Capital Management sold 33,605 ANI Pharmaceuticals shares in Q3 2020, an estimated $1.09M.
Cadence Capital Management first reported a position in ANI Pharmaceuticals in Q1 2015 and held it in 22 quarters.
Cadence Capital Management's ANI Pharmaceuticals position peaked at $4.28M in Q1 2019.
116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.